Pay in 4 interest-free payments of $6.47 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Tirzepatide (a GLP-1R/GIPR dual agonist), licensed by the MHRA as Mounjaro for type 2 diabetes and, subject to NICE guidance, for weight management in adults with obesity, achieved mean weight reductions of up to approximately 22% in the SURMOUNT-1 trial (NEJM 2022) a notable improvement over GLP-1R monotherapy
Though their use is supported by various professional guidelines, their injectable route of administration has been considered a barrier to widespread adoption
30
When you book your appointment at Defining Beauty Wellness & Med Spa in Tampa, FL, youre choosing a team of healthcare professionals who are committed to your success and well-being
